EP
JAZZ icon

Essential Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Essential Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$79K Buy
328
+230
+235% +$50.4K 0.04% 483
2026
Q1 		$18.5K Buy
98
+21
+27% +$3.67K 0.01% 958
2025
Q4 		$13.1K Buy
77
+1
+1% +$153 ﹤0.01% 1063
2025
Q3 		$10K Buy
76
+8
+12% +$960 ﹤0.01% 1155
2025
Q2 		$7.22K Buy
+68
New +$7.39K ﹤0.01% 944

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Essential Partners's JAZZ Position: Q2 2026 in Review

Essential Partners increased its Jazz Pharmaceuticals (JAZZ) stake by 235% in Q2 2026, buying an estimated $50.4K and bringing the position to 328 shares worth $79K. The position accounts for 0.04% of the portfolio, ranked #483.

Essential Partners first reported a position in JAZZ in Q2 2025 and has held it in 5 quarters since. 643 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Essential Partners held 328 shares of Jazz Pharmaceuticals worth $79K as of Q2 2026.
  • Essential Partners bought 230 Jazz Pharmaceuticals shares in Q2 2026, an estimated $50.4K.
  • Jazz Pharmaceuticals made up 0.04% of Essential Partners's portfolio in Q2 2026, its #483 holding.
  • Essential Partners first reported a position in Jazz Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 643 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.